Cárcel-Márquez Jara, Muiño Elena, Gallego-Fabrega Cristina, Cullell Natalia, Lledós Miquel, Llucià-Carol Laia, Sobrino Tomás, Campos Francisco, Castillo José, Freijo Marimar, Arenillas Juan Francisco, Obach Victor, Álvarez-Sabín José, Molina Carlos A, Ribó Marc, Jiménez-Conde Jordi, Roquer Jaume, Muñoz-Narbona Lucia, Lopez-Cancio Elena, Millán Mònica, Diaz-Navarro Rosa, Vives-Bauza Cristòfol, Serrano-Heras Gemma, Segura Tomás, Ibañez Laura, Heitsch Laura, Delgado Pilar, Dhar Rajat, Krupinski Jerzy, Delgado-Mederos Raquel, Prats-Sánchez Luis, Camps-Renom Pol, Blay Natalia, Sumoy Lauro, de Cid Rafael, Montaner Joan, Cruchaga Carlos, Lee Jin-Moo, Martí-Fàbregas Joan, Férnandez-Cadenas Israel
Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain.
Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Front Cardiovasc Med. 2022 Jul 8;9:940696. doi: 10.3389/fcvm.2022.940696. eCollection 2022.
Occult atrial fibrillation (AF) is one of the major causes of embolic stroke of undetermined source (ESUS). Knowing the underlying etiology of an ESUS will reduce stroke recurrence and/or unnecessary use of anticoagulants. Understanding cardioembolic strokes (CES), whose main cause is AF, will provide tools to select patients who would benefit from anticoagulants among those with ESUS or AF. We aimed to discover novel loci associated with CES and create a polygenetic risk score (PRS) for a more efficient CES risk stratification.
Multitrait analysis of GWAS (MTAG) was performed with MEGASTROKE-CES cohort ( = 362,661) and AF cohort ( = 1,030,836). We considered significant variants and replicated those variants with MTAG -value < 5 × 10 influencing both traits (GWAS-pairwise) with a -value < 0.05 in the original GWAS and in an independent cohort ( = 9,105). The PRS was created with PRSice-2 and evaluated in the independent cohort.
We found and replicated eleven loci associated with CES. Eight were novel loci. Seven of them had been previously associated with AF, namely, , and . locus had never been associated with CES/AF, leading its index variant to a missense change (R1045W). The PRS generated has been significantly associated with CES improving discrimination and patient reclassification of a model with age, sex, and hypertension.
The loci found significantly associated with CES in the MTAG, together with the creation of a PRS that improves the predictive clinical models of CES, might help guide future clinical trials of anticoagulant therapy in patients with ESUS or AF.
隐匿性房颤(AF)是不明来源栓塞性卒中(ESUS)的主要原因之一。了解ESUS的潜在病因将降低卒中复发率和/或减少抗凝剂的不必要使用。了解主要由房颤引起的心源性栓塞性卒中(CES),将为在ESUS或房颤患者中选择可能从抗凝剂治疗中获益的患者提供方法。我们旨在发现与CES相关的新基因座,并创建一个多基因风险评分(PRS),以更有效地对CES进行风险分层。
使用MEGASTROKE-CES队列(n = 362,661)和房颤队列(n = 1,030,836)进行全基因组关联研究的多性状分析(MTAG)。我们考虑了显著变异,并在原始全基因组关联研究和一个独立队列(n = 9,105)中,用MTAG p值<5×10且影响两个性状(全基因组关联研究成对分析)、原始全基因组关联研究p值<0.05的变异进行重复验证。使用PRSice-2创建PRS,并在独立队列中进行评估。
我们发现并重复验证了11个与CES相关的基因座。其中8个是新基因座。其中7个先前已与房颤相关,即……基因座从未与CES/房颤相关,其索引变异导致错义改变(R1045W)。所生成的PRS与CES显著相关,改善了包含年龄、性别和高血压的模型的辨别力和患者重新分类。
在MTAG中发现的与CES显著相关的基因座,以及创建的能改善CES预测临床模型的PRS,可能有助于指导未来针对ESUS或房颤患者的抗凝治疗临床试验。